PEOPLE - DiaSys makes appointment:
This article was originally published in Clinica
Executive Summary
Diagnostics firm DiaSys (Waterbury, Connecticut) has formed a medical advisory board to assist with R&D projects related to expanding its product lines. Dr John Chen, co-founder of IVD firms BioCheck, Rapid Diagnostics, Medix Biotech (acquired by Genzyme in 1992) and Pacific Biotech (acquired by Eli Lilly), has been appointed to the board. He is joined by: Lynne Garcia, director of LSG Associates, a provider of diagnostic medical parasitology and healthcare administration; Anthony Moody, formerly head biomedical scientist at the Hospital of Tropical Diseases; and Dr Berry Schumann, who is currently medical director for Diagnostic Oncology CRO, a position he has held since 2001.
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.